GlassScriptPhysician profile
Jacinto Del Mazo
NPI 1104891316
$9,363.94
in general payments reported to CMS, 2019-2025
68 companies · $1,159 in 2025
The $1,159 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $287 · 2021: $2,086 · 2022: $1,869 · 2023: $1,984 · 2024: $1,606 · 2025: $1,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,748.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,453.21 | 2019-2025 | Linzess, Viberzi, Creon |
| Novo Nordisk INC | $890.00 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $668.93 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $553.69 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $454.60 | 2021-2025 | Repatha, Otezla, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $408.84 | 2019-2023 | Xifaxan, Cycloset, Trulance |
| Glaxosmithkline, LLC. | $396.16 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $256.49 | 2021-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.78 | 2021-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $219.92 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $216.70 | 2019-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $205.00 | 2019-2025 | Belsomra, Steglatro, Capvaxive |
| Novartis Pharmaceuticals Corporation | $201.01 | 2021-2023 | |
| Dexcom, INC. | $182.80 | 2021-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $158.34 | 2022-2025 | Rexulti |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacinto Del Mazo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.